Heerlen, NL, 01 Apr 2020 18:30 CEST
Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, today announces the completion of its acquisition of Glycom A/S (“Glycom”), the world's leading supplier of Human Milk Oligosaccharides (HMO) for an enterprise value of €765 million. The acquisition of Glycom was first announced on 21 February 2020.
DSM is a leading global solutions supplier to the Early Life Nutrition industry with a unique portfolio including nutritional lipids, vitamins and nutrient premixes. With the acquisition of Glycom, DSM adds HMOs to its portfolio. The high-growth HMO market is set to deliver novel ingredients for next generation Early Life Nutrition solutions.
Glycom is the only fully-integrated HMO provider in the world with its own product development, preclinical and clinical development, regulatory and large-scale production with an exciting innovation roadmap for next-generation HMOs. As HMOs are believed essential for the development of immunity, cognitive and digestive functions, there is significant interest in HMOs for the dietary supplement market, unmet medical nutrition needs like irritable bowel syndrome, food & beverage applications and for pet foods.
Senior Communications Manager
+31 45 578 2420
Vice-President Investor Relations
+31 45 578 2864